Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-23T08:35:36.412Z Has data issue: false hasContentIssue false

Academic psychiatry and the pharmaceutical industry: useful partnership or dangerous interaction?

Published online by Cambridge University Press:  18 May 2011

Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorials
Copyright
Copyright © Cambridge University Press 2007

References

REFERENCES

Adams, C. & Jayaram, M. (2007). Do findings from new trials for schizophrenia fit with existing evidence: not duped just beguiled? Epidemiologia e Psichiatria Sociale 16, 199202.Google Scholar
Barbui, C. & Cipriani, A. (2007). Evidence-based psychopharmacology: an agenda for the future. Evidence Based Mental Health 10, 46.Google Scholar
Barbui, C. & Garattini, S. (2007). Regulatory policies on medicines for psychiatric disorders: is Europe on target? British Journal of Psychiatry 190,9193.Google Scholar
Healy, D. (2007). The engineers of human souls & academia. Epidemiologia e Psichiatria Sociale 16, 205211.Google Scholar
Moncrieff, J. (2007). Co-opting psychiatry: the alliance between academic psychiatry and the pharmaceutical industry. Epidemiologia e Psichiatria Sociale 16, 192196.Google Scholar
Pilling, S. & Price, K. (2006). Developing and implementing clinical guidelines: lessons from the NICE Schizophrenia Guideline. Epidemiologia e Psichiatria Sociale 15, 109116.Google Scholar
Tognoni, G. & Franzosi, M.G. (2005). [Experimenting in Italy: from GIS-SI to the Ministerial Decree]. Recenti Progressi in Medicina 96, 9294.Google Scholar
Tohen, M. (2007). Collaborations between academic psychiatry and the pharmaceutical industry: A perspective from industry. Epidemiologia e Psichiatria Sociale 16, 197198.Google Scholar